Entrada TherapeuticsTRDA +8.40%23 Current Ratio is 13.90 as of Mar. 2026, which is 21% above its 10-year median of 11.52. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Entrada Therapeutics ranks better than 85.1% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Entrada Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 13.90.
Entrada Therapeutics has a current ratio of 13.90. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Entrada Therapeutics's Current Ratio or its related term are showing as below:
TRDA'
s Current Ratio Range Over the Past 10 Years
Min: 2.32 Med: 11.52 Max: 44.46
Current: 13.9
During the past 7 years, Entrada Therapeutics's highest Current Ratio was 44.46. The lowest was 2.32. And the median was 11.52.
TRDA's Current Ratio is ranked better than 85.1% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs TRDA: 13.90
Entrada Therapeutics (NAS:TRDA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Entrada Therapeutics Current Ratio Related Terms
Entrada Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRDA vs SABS, ACIU, AVXL: Current Ratio Comparison
For the Biotechnology subindustry, Entrada Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (TRDA) has a Current Ratio of 13.90 as of Mar. 2026. This is 21% above median its historical median of 11.52. Over the past decade, Entrada Therapeutics' Current Ratio has ranged from 2.32 to 44.46. According to the industry distribution chart, Entrada Therapeutics ranks #211 out of 1416 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Entrada Therapeutics' Current Ratio too high?
Entrada Therapeutics' current Current Ratio of 13.90 is 21% above median its 10-year median of 11.52. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 44.46. The Biotechnology industry median Current Ratio is 3.89. Entrada Therapeutics' value of 13.90 is 257.8% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #211 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Current Ratio compare to SABS and ACIU?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #211 out of 1416 companies for Current Ratio. This places Entrada Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Entrada Therapeutics' value of 13.90 is 257.8% above this benchmark. Historically, Entrada Therapeutics' own Current Ratio has ranged from 2.32 to 44.46 over the past decade. While the company's 10-year median is 11.52 vs. the industry median of 3.89, Entrada Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current Current Ratio of 13.90 is 257.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current Current Ratio is 13.90, which is 21% above median its own 10-year median of 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.74 — trading 741.3% above its estimated fair value. The current Current Ratio is 13.90, which is 21% above median its 10-year median of 11.52 and 257.8% above the Biotechnology industry median of 3.89. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Current Ratio is 13.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.74 is trading 741.3% above its estimated GF Value™ of $0.92.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
Current Ratio: 13.90 (21% above median its 10-year median of 11.52)
GF Value™: $0.92 vs. price of $7.74 (741.3% above fair value)
Industry Position: 257.8% above the Biotechnology median (#211 of 1416)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score
Get the complete analysis for TRDA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
